Brain stimulation therapy shows positive results for rapid relief of flu-related sleep problems

A noninvasive brain stimulation therapy could offer fast relief for flu-related sleep issues by calming brain activity and immune responses, according to a new study published in Translational Psychiatry by Nature in March 2026.

Sleep issues are a common but often overlooked complication of influenza, even after fever and respiratory symptoms improve. The virus can trigger a strong immune response that leads to inflammation and changes in brain function, especially in areas that help control the sleep-wake cycle, according to study authors who are urologists and phycologists in Shaanxi, China.

This process in the time of a flu is sometimes described as an “immune-brain” pathway that can disrupt normal sleep patterns and lead to insomnia, fatigue and reduced daytime focus. Standard treatments such as antivirals and supportive care can shorten illness, but they do little to address these neurologic symptoms.

Researchers are now exploring non-drug options including repetitive transcranial magnetic stimulation (rTMS), which uses targeted magnetic pulses to stimulate nerve cells in the brain. Already cleared by the FDA for depression, rTMS can help regulate activity in the prefrontal cortex, a region tied to both sleep and emotional control.

In this study, researchers evaluated whether adding rTMS to standard flu care could improve sleep outcomes. This effort is performed to calm overactive brain regions while also influencing immune markers linked to inflammation, offering a potential new way to manage flu-related sleep disturbances in the acute phase.

To conduct this study, data from adults ages 18 to 40 who were treated for acute influenza between 2023 and 2025 were analyzed. From an initial pool of patients, 55 met strict criteria and were grouped based on treatment approaches. One group received standard care alone, while another received standard care plus rTMS delivered once daily for three days.

Each session lasted about 20 to 30 minutes and used targeted magnetic pulses to stimulate the brain. A third group of healthy folks served as controls. To measure outcomes, the researchers used sleep studies, patient-reported sleep scores, brain imaging and blood tests that tracked markers of inflammation.

Assessments were conducted before and after treatment within a five-day window to capture short-term changes. While the study was not randomized, outcome measures were evaluated by blinded reviewers to reduce bias and strengthen the reliability of the findings.

The results revealed a clear link between flu infection and sleep disruption, along with changes in brain function and immune activity. Genetic and clinical analyses found that the flu was associated with insomnia and structural changes in 27 brain regions, with the frontal lobe most affected.

Key immune markers, including immunoglobulin M and neutrophils, were strongly tied to both sleep symptoms and changes in brain structure. This finding suggests these markers play a prime role in the pathway connecting infection to sleep disorders. Before treatment, patients with the flu had poorer sleep duration and efficiency compared with healthy patients, along with increased activity in frontal brain regions linked to sleep regulation.

After three days of rTMS, patients showed improvements in sleep quality and structure compared with those receiving standard care alone. Brain imaging also showed reduced overactivity in the right orbitofrontal cortex and left ventrolateral prefrontal cortex, areas tied to insomnia.

Aside from positive results, the study has a number of strengths, including its use of multiple objective tools such as brain imaging, sleep studies and immune markers to better understand how influenza affects sleep and how rTMS could help. It also offers early insight into a brain-immune pathway and identifies potential biomarkers for treatment.

However, there are limitations, including its small sample size, lack of randomization and focus on younger healthy adults, which could affect how widely the findings apply to different age groups.

Authors suggest larger randomized trials and further research to clarify treatment targets and better understand how rTMS works in this setting.